Small tumors, intermediate models, big hopes

Journal of Clinical Oncology

Volumn 28, Issue 29, 2010, Pages 4407-4409

  Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DALOTOZUMAB; ERLOTINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EDITORIAL; HUMAN; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 79951979524     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.0094     Document Type: Editorial

References (16)

1. Moertel CG: Karnofsky memorial lecture: An odyssey in the land of small tumors. J Clin Oncol 5:1502-1522, 1987
2. Zikusoka MN, Kidd M, Eick G, et al: The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104:2292-2309, 2005 (Pubitemid 41691550)
3. Raymond E, Niccoli-Sire Y, Bang Y, et al: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). Presented at the 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 127)
4. Yao JC, Shah MH, Ito T, et al: Everolimus versus placebo in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3). Ann Oncol doi:10.1093/annonc/mdq340
5. Chiu C, Nozawa H, Hanahan D: Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 28:4425-4433, 2010
6. Teicher BA: Tumor models for efficacy determination. Mol Cancer Ther 5:2435-2443, 2006
7. Bergsland EK, Venook AP, Ko AH, et al: RAD001 and erlotinib in patients with neuroendocrine tumors. National Institutes of Health, 2009. http://clinicaltrials.gov/ct2/show/NCT00843531
8. Hanahan D: Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115-122, 1985
9. Modlin IM, Moss SF, Chung DC, et al: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 100:1282-1289, 2008
10. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006 (Pubitemid 43259931)
11. Yao JC, Phan AT, Chang DZ, et al: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 26:4311-4318, 2008
12. Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28:69-76, 2010
13. Duran I, Kortmansky J, Singh D, et al: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154, 2006 (Pubitemid 44660065)
14. Hobday TJ, Mahoney ME, Lloyd R, et al: Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 23:334s, 2005 (suppl; abstr 4083)
15. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, et al: A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 28:235s, 2010 (suppl; abstr 3008)
16. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 458:719-724, 2009